Conversely, Afatinib, a multi-targeted and irreversible TKI targeting EGFR, ErbB2 and ErbB4, has shown clinical benefits in different cohorts of HNSCC patients, comparable or superior to that of Cetuximab (1, 115). The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.